CDP-Choline Sodium
CAS 33818-15-4
Purity≥98%
Ingredient for formulation and biochemical R&D
For B2B ingredient sourcing, request the specification, batch COA, sample, packaging and lead-time confirmation. Explore nutrition & functional ingredients.
Confirm current-lot COA and target specification before qualification.
Key Specifications
| Product Positioning | Ingredient for formulation and biochemical R&D |
| Application Scenarios | formulation development |
| CAS Number | 33818-15-4 |
| Purity | ≥98% |
| Molecular Formula | C₁₄H₂₅N₄NaO₁₁P₂ · xH₂O |
| Molecular Weight | 510.31 g/mol (anhydrous moiety) |
| Appearance | Refer to the batch COA |
| Solubility | Evaluate dissolution at the target formulation concentration |
| Storage | Follow the supplied batch label and storage instructions |
| Shelf Life | 2 years under the specified storage conditions |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
Citicoline sodium (CAS 33818-15-4) is the sodium salt of CDP-choline. PathGene Biotech supplies this material under an in-house specification with a purity requirement of ≥98%. The supplied COA identifies the material as C14H25N4NaO11P2·xH2O; 510.31 g/mol refers to the anhydrous moiety. It is a separate product from citicoline CAS 987-78-0, so salt identity, water content and assay basis should be checked when specifying or comparing materials.
Test items, specifications and batch results are shown here; request the formal COA through the card below.
Batch No.
PG02N-260714
Test date
2026-07-15
Specification
In-house
Pack size
25 kg/carton
Storage
Follow the supplied batch label and storage instructions
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White crystalline powder | Off-white powder |
| Identification | Positive reaction; HPLC retention time and IR spectrum match reference | Complies |
| Solution clarity and color | Clear and colorless | Complies |
| Purity | ≥98% | 99.9% |
| Assay | 98.0–102.0% | 99.5% |
| Loss on drying | ≤6.0% | 2.4% |
| pH | 6.0–7.5 | 6.88 |
| 5′-CMP | ≤0.3% | 0.090% |
| Other individual impurity | ≤0.2% | Complies |
| Total of other impurities | ≤0.7% | Complies |
| Methanol | ≤0.3% | Complies |
| Ethanol | ≤0.5% | Complies |
| Acetone | ≤0.5% | Complies |
| Chloride | ≤0.05% | Complies |
| Iron | ≤0.01% | Complies |
| Ammonium | ≤0.05% | Complies |
| Free phosphate | ≤0.1% | Complies |
| Heavy metals | ≤5 ppm | Complies |
| Arsenic | ≤1 ppm | Complies |
| Total plate count | ≤1000 CFU/g | Complies |
| Yeast and mold | ≤100 CFU/g | Complies |
| E. coli | Negative | Not detected |
| Salmonella | Negative | Not detected |
| Bacterial endotoxins | ≤0.30 EU/mg | Complies |
This page shows a batch-data summary only. No direct COA file link is provided; request the signed document through the form below.
Oral liquid
Injectable formulation development
Marketed oral solutions explicitly use citicoline as the sodium salt. Define the active-moiety declaration, concentration and excipient system before selecting the raw-material specification.
Evidence: AEMPS product information confirms the marketed dosage form; it does not certify PathGene material or establish equivalence of a new formulation.Source
Assess the full raw-material and finished-product requirements for the intended process. An endotoxin compliance result alone does not demonstrate sterility or suitability for injection.
Evidence: AEMPS lists a citicoline sodium injectable presentation. Application evidence is distinct from the qualification of this supplied grade.Source
Literature-Supported Research Directions
Human oral CDP-choline research examined changes in circulating choline and uridine, providing a basis for studying precursor availability for membrane phospholipid synthesis. Salt form and formulation equivalence require separate assessment.
Citation: Wurtman et al. (2000). Effect of oral CDP-choline on plasma choline and uridine levels in humans.View source
An early human phosphorus magnetic resonance spectroscopy study observed changes in selected brain phospholipid metabolites after oral citicoline. These findings support investigation of phospholipid turnover; metabolic-marker changes alone do not establish clinical efficacy.
Citation: Babb et al. Psychopharmacology (2002), 161:248–254.View source
A 12-week placebo-controlled trial in 100 adults aged 50–85 with age-associated memory impairment reported improvements in secondary episodic and composite memory outcomes using a specific branded citicoline ingredient. This supports further research, not direct clinical validation of PathGene citicoline sodium.
Citation: Nakazaki et al. Journal of Nutrition (2021), 151:2153–2160.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
1 kg
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Purity and assay are separate COA items: the specification is ≥98% for purity and 98–102% for assay. Batch PG02N-260714 reports 99.9% purity, 99.5% assay and 2.4% loss on drying. These are batch results, not minimum guarantees for every future batch. Confirm the analytical and calculation basis before comparing suppliers. Its endotoxin result is reported as Complies against ≤0.30 EU/mg, not as a numerical measured concentration or an external test result.
Confirm the salt form, water content and assay basis before formulation, including whether the declared quantity is expressed as citicoline or citicoline sodium. For oral liquids, evaluate dissolution at the target concentration, pH, excipient compatibility and storage stability. Marketed injectable products demonstrate a dosage-form application, but do not establish this material as sterile or injection-ready. Match the intended use to the required material grade and finished-product controls.
They share the citicoline active moiety but differ in salt identity and CAS number. Check water content, assay basis and declared active quantity rather than replacing one material by equal weight without assessment.
The supplied COA identifies C14H25N4NaO11P2·xH2O. The listed 510.31 g/mol is for the anhydrous moiety; use the batch water or loss-on-drying result and specified assay basis when assessing the supplied material.
The in-house specification lists purity ≥98% and assay 98–102%. Batch PG02N-260714 reports 99.9% and 99.5%, respectively. Request the COA for the offered batch.
Batch PG02N-260714 reports Complies against an endotoxin limit of ≤0.30 EU/mg. This is not an exact measured concentration, a third-party report or proof of sterility.
Samples are available on request. Please provide the intended application, target market, quantity and quality requirements. The documented packaging is 25 kg/carton; MOQ and lead time require confirmation.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Issued with each shipment
Related Products
Citicoline (CDP-Choline)
Calcium L-5-Methyltetrahydrofolate
Interested in CDP-Choline Sodium?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
